Myelofibrosis Clinical Trials

32 studies are recruiting for myelofibrosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

   The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assesse…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope - Duarte Main Site, Duarte, California

   Locations

   70 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT05980806 on ClinicalTrials.gov

2. MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

   The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic pr…

   Stage

   Not phased

   Ages

   18 and older

   Site

   MPN Research Foundation, Chicago, Illinois

   Locations

   2 in total

   Run by

   MPN Research Foundation

   See if you can join NCT07362225 on ClinicalTrials.gov

3. Two Step Haplo With Radiation Conditioning

   This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031897 on ClinicalTrials.gov

4. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Birmingham, Alabama

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

5. Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

   This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UAB Hospital, Birmingham, Alabama

   Locations

   215 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT06479135 on ClinicalTrials.gov

6. Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

   This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to th…

   Stage

   Not phased

   Ages

   55 and older

   Site

   Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT02934477 on ClinicalTrials.gov

7. Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

   This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   19 in total

   Run by

   Telios Pharma, Inc.

   See if you can join NCT05280509 on ClinicalTrials.gov